• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    DermTech Reports Fourth-Quarter 2023 Financial Results

    2/29/24 4:01:00 PM ET
    $DMTK
    Medical Specialities
    Health Care
    Get the next $DMTK alert in real time by email

    - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year

    - Test revenue increased 38 percent versus the fourth quarter of 2022

    - Estimated cash runway into the first quarter of 2025

    DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results.

    "We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024," said Bret Christensen, CEO, DermTech. "We've aligned our commercial effort with the aim to maximize revenue by focusing on existing customers and reimbursed tests. We expanded our Medicare proportion of billable samples from 23 percent to an all-time record high of 28 percent in the last three quarters."

    Christensen continued, "We've also delivered on our commitment to find additional operating efficiencies and being diligent with the allocation of our resources. We now plan to achieve approximately $40 million in annualized total operating expense reductions compared to 2022, as a result of our restructuring actions during the last several months."

    Christensen concluded, "We have a great technology that can significantly enhance the standard of care for evaluating melanoma, while also lowering healthcare costs and providing a better patient experience. We continue to be inspired by the patient stories we often hear where we've made a significant difference in their lives."

    Fourth-Quarter 2023 Financial Results

    • Billable sample volume declined 11 percent from the fourth quarter of 2022 to approximately 15,580.
    • Test revenue was $3.7 million, up 38 percent from the fourth quarter of 2022, primarily due to a higher ASP for the DMT.
    • Total revenue was $3.9 million, a 31 percent increase from the fourth quarter of 2022, driven by higher test revenue.
    • Cost of test revenue was $3.4 million, a 4 percent increase from the fourth quarter of 2022, yielding a test gross margin of 7 percent, compared to negative 22 percent for the fourth quarter of 2022. Cost of test revenue increased primarily because of higher infrastructure costs related to the Company's new facility.
    • Sales and marketing expenses were $8.4 million, a 38 percent decrease from the fourth quarter of 2022. The decrease was primarily attributable to lower employee-related and marketing expenditures.
    • Research and development expenses were $3.3 million, a 34 percent decrease from the fourth quarter of 2022, largely due to lower employee-related and lab supplies costs.
    • General and administrative expenses were $8.4 million, a 14 percent decrease from the fourth quarter of 2022. The decrease was driven primarily by lower employee-related costs, offset by higher infrastructure costs related to the Company's new facility.
    • Net loss was $19.1 million, or ($0.56) per share, which included $3.2 million of non-cash stock-based compensation expense, as compared to $28.2 million, or ($0.93) per share, for the fourth quarter of 2022, which included $5.3 million of non-cash stock-based compensation expense.
    • Cash, cash equivalents, restricted cash and short-term marketable securities were $59.3 million as of December 31, 2023. DermTech believes it should have sufficient cash resources to fund its planned operations into the first quarter of 2025, not to exceed 12 months from the February 29, 2024 filing date of the Company's Form 10-K.

    Conference Call Information

    As previously announced, the Company will host a conference call to discuss its results at 5:00 p.m. ET on Thursday, February 29, 2024. For participants interested in asking questions during the teleconference, please register. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during the live teleconference, but advance registration is advised. For participants interested in listening only, please register for the webcast. For those unable to participate in the live call and webcast, a webcast replay will be available on the Company's website shortly after the conclusion of the call.

    About DermTech

    DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics technology. DermTech's mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected using its Smart StickersTM. DermTech develops and markets products that facilitate the assessment of melanoma. For additional information, please visit DermTech.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "aim," "runway," "outlook," "anticipate," "intend," "plan," "strive," "may," "will," "sustain," "could," "should," "believe," "predict," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech's products and the market opportunity for these products; expectations regarding DermTech's potential growth, scale, patient reach, financial outlook, including its cash runway and future financial performance DermTech's ability to increase its test volume, revenue and the proportion of reimbursed billable tests and control or reduce cost, expenses and cash burn, including as a result of DermTech's recent restructuring actions; and expectations regarding agreements with or reimbursement or cash collection patterns from government payers (including Medicare) or commercial payers and related billing practices or number of covered lives. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech's ability to obtain additional capital when and as needed or on acceptable terms; (3) the existence of favorable or unfavorable clinical guidelines for DermTech's tests; (4) the reimbursement of DermTech's tests by government payers (including Medicare) and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech's products; (6) DermTech's ability to grow, manage growth and retain its key employees and maintain or improve its operating efficiency and reduce operating expenses; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech's products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; (9) DermTech's ability to continue as a going concern and (10) other risks and uncertainties included in the "Risk Factors" section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the "SEC"), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

    DERMTECH, INC.

    Consolidated Statements of Operations (in thousands, except share and per share data)

     

     

     

     

     

     

     

     

    Three Months Ended December 31,

     

    Twelve Months Ended December 31,

     

     

    2023

     

    2022

     

    2023

     

    2022

    Revenues:

     

     

     

     

     

     

     

     

    Test revenue

     

    $

    3,702

     

     

    $

    2,692

     

     

    $

    14,384

     

     

    $

    13,790

     

    Contract revenue

     

     

    222

     

     

     

    302

     

     

     

    912

     

     

     

    728

     

    Total revenues

     

     

    3,924

     

     

     

    2,994

     

     

     

    15,296

     

     

     

    14,518

     

    Cost of revenues:

     

     

     

     

     

     

     

     

    Cost of test revenue

     

     

    3,431

     

     

     

    3,292

     

     

     

    14,792

     

     

     

    13,702

     

    Cost of contract revenue

     

     

    53

     

     

     

    58

     

     

     

    228

     

     

     

    169

     

    Total cost of revenues

     

     

    3,484

     

     

     

    3,350

     

     

     

    15,020

     

     

     

    13,871

     

    Gross (loss) profit

     

     

    440

     

     

     

    (356

    )

     

     

    276

     

     

     

    647

     

    Operating expenses:

     

     

     

     

     

     

     

     

    Sales and marketing

     

     

    8,422

     

     

     

    13,598

     

     

     

    44,995

     

     

     

    58,674

     

    Research and development

     

     

    3,348

     

     

     

    5,097

     

     

     

    15,239

     

     

     

    24,052

     

    General and administrative

     

     

    8,422

     

     

     

    9,828

     

     

     

    43,781

     

     

     

    36,086

     

    Total operating expenses

     

     

    20,192

     

     

     

    28,523

     

     

     

    104,015

     

     

     

    118,812

     

    Loss from operations

     

     

    (19,752

    )

     

     

    (28,879

    )

     

     

    (103,739

    )

     

     

    (118,165

    )

    Other income:

     

     

     

     

     

     

     

     

    Interest income, net

     

     

    660

     

     

     

    641

     

     

     

    2,846

     

     

     

    1,341

     

    Change in fair value of warrant liability

     

     

    1

     

     

     

    15

     

     

     

    5

     

     

     

    141

     

    Total other income

     

     

    661

     

     

     

    656

     

     

     

    2,851

     

     

     

    1,482

     

    Net loss

     

    $

    (19,091

    )

     

    $

    (28,223

    )

     

    $

    (100,888

    )

     

    $

    (116,683

    )

    Weighted average shares outstanding used in computing net loss per share, basic and diluted

     

     

    34,326,638

     

     

     

    30,245,264

     

     

     

    32,641,376

     

     

     

    30,038,959

     

    Net loss per share of common stock outstanding, basic and diluted

     

    $

    (0.56

    )

     

    $

    (0.93

    )

     

    $

    (3.09

    )

     

    $

    (3.88

    )

    DERMTECH, INC.

    Consolidated Balance Sheets (in thousands, except share and per share data)

     

     

     

     

     

     

     

    December 31, 2023

     

    December 31, 2022

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    36,741

     

     

    $

    77,757

     

    Short-term marketable securities

     

     

    19,123

     

     

     

    48,411

     

    Accounts receivable

     

     

    2,584

     

     

     

    4,172

     

    Inventory

     

     

    1,004

     

     

     

    1,757

     

    Prepaid expenses and other current assets

     

     

    2,300

     

     

     

    3,940

     

    Total current assets

     

     

    61,752

     

     

     

    136,037

     

    Property and equipment, net

     

     

    4,988

     

     

     

    6,375

     

    Operating lease right-of-use assets

     

     

    51,722

     

     

     

    56,007

     

    Restricted cash

     

     

    3,468

     

     

     

    3,488

     

    Other assets

     

     

    —

     

     

     

    168

     

    Total assets

     

    $

    121,930

     

     

    $

    202,075

     

    Liabilities and Stockholders' Equity

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable

     

    $

    1,484

     

     

    $

    2,419

     

    Accrued compensation

     

     

    6,664

     

     

     

    7,894

     

    Accrued liabilities

     

     

    2,017

     

     

     

    3,464

     

    Short-term deferred revenue

     

     

    196

     

     

     

    109

     

    Current portion of operating lease liabilities

     

     

    3,069

     

     

     

    1,634

     

    Current portion of finance lease obligations

     

     

    17

     

     

     

    116

     

    Total current liabilities

     

     

    13,447

     

     

     

    15,636

     

    Warrant liability

     

     

    —

     

     

     

    5

     

    Long-term finance lease obligations, less current portion

     

     

    38

     

     

     

    53

     

    Operating lease liabilities, long-term

     

     

    51,270

     

     

     

    54,028

     

    Total liabilities

     

     

    64,755

     

     

     

    69,722

     

    Stockholders' equity:

     

     

     

     

    Common stock, $0.0001 par value per share; 100,000,000 and 50,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 34,524,677 and 30,297,408 shares issued and outstanding at December 31, 2023 and 2022, respectively

     

     

    3

     

     

     

    3

     

    Additional paid-in capital

     

     

    480,929

     

     

     

    456,171

     

    Accumulated other comprehensive income/(loss)

     

     

    178

     

     

     

    (774

    )

    Accumulated deficit

     

     

    (423,935

    )

     

     

    (323,047

    )

    Total stockholders' equity

     

     

    57,175

     

     

     

    132,353

     

    Total liabilities and stockholders' equity

     

    $

    121,930

     

     

    $

    202,075

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240229006238/en/

    Get the next $DMTK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DMTK

    DatePrice TargetRatingAnalyst
    7/18/2022$48.00Outperform
    Oppenheimer
    6/14/2022$38.00 → $19.00Buy
    BTIG Research
    1/7/2022$26.00Overweight
    Stephens
    1/7/2022Overweight
    Stephens & Co.
    10/15/2021$50.00Outperform
    Cowen
    More analyst ratings

    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Sun Kevin M covered exercise/tax liability with 445 shares, decreasing direct ownership by 0.17% to 269,216 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/12/24 8:07:07 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Akhavan Ramin covered exercise/tax liability with 3,745 shares, decreasing direct ownership by 3% to 128,425 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:06:44 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Sun Kevin M covered exercise/tax liability with 4,945 shares, decreasing direct ownership by 2% to 269,661 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:04:16 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DermTech Files for Voluntary Chapter 11 Protection

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech

      6/18/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports First-Quarter 2024 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from

      5/14/24 4:05:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    SEC Filings

    See more
    • DermTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/20/24 4:03:19 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/18/24 8:10:13 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Other Events

      8-K - DermTech, Inc. (0001651944) (Filer)

      5/17/24 4:05:27 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on DermTech with a new price target

      Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00

      7/18/22 9:13:48 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • BTIG Research reiterated coverage on DermTech with a new price target

      BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously

      6/14/22 8:37:49 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • Stephens initiated coverage on DermTech with a new price target

      Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00

      1/7/22 7:32:05 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Leadership Updates

    Live Leadership Updates

    See more
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for

      11/7/23 4:13:58 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options

      10/18/23 3:55:34 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Appoints Mark Aguillard as Chief Commercial Officer

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech's overall commercial strategy and execution. Commenting on Mr. Aguillard's appointment, Bret Christensen, DermTech's CEO said, "I'd like to welcome Mark to the team. We are confident that his demonstrated success and wide breadth of commercial and payer access experience will serve us well during this transformational period as we focus on generating reimbursed tests to grow revenue. Mark's leadership will be i

      9/11/23 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DermTech Inc.

      SC 13G - DermTech, Inc. (0001651944) (Subject)

      4/26/24 6:19:55 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by DermTech Inc. (Amendment)

      SC 13G/A - DermTech, Inc. (0001651944) (Subject)

      2/8/24 5:18:40 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by DermTech Inc. (Amendment)

      SC 13D/A - DermTech, Inc. (0001651944) (Subject)

      12/12/23 4:19:36 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Financials

    Live finance-specific insights

    See more
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports Fourth-Quarter 2023 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year - Test revenue increased 38 percent versus the fourth quarter of 2022 - Estimated cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. "We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024," said Bret Christensen, CEO, DermTech. "We've aligned our commer

      2/29/24 4:01:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Announces Release Date for Fourth-quarter 2023 Financial Results

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during

      2/13/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care